LOUISVILLE, Ky., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a BrightSpring company and leading independent Specialty Pharmacy, was selected by Eisai to be the national specialty pharmacy provider for Leqembi®, a cutting-edge treatment for Alzheimer’s disease.
“We’re proud of the work CareMed is doing with manufacturers and prescribers to improve and extend the lives of patients living with mild cognitive impairment and dementia, bringing more treatment options to Alzheimer’s disease,” said BrightSpring’s President and CEO, Jon Rousseau. “CareMed’s partnership with Eisai shows their strong commitment to increasing patient access to innovative medications and treatments, while delivering comprehensive support and care to patients and their loved ones."
Leqembi is a monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta in the treatment of Alzheimer’s disease. The medication was tested in numerous clinical trials with patients diagnosed with mild cognitive impairment or mild dementia stage of disease. The FDA approval of Leqembi is based on the results of the Phase III clinical trial, which compared Leqembi to placebo in patients 50 to 90 years of age with early Alzheimer’s disease. The study randomized 1795 patients in a 1:1 ratio to receive either intravenous Leqembi or placebo. Patients who received Leqembi showed slowed progression of cognitive impairment over an 18-month period compared to those taking the placebo.
“At CareMed, we’re constantly looking for new opportunities to expand our portfolio of breakthrough treatments and therapies for patients living with devastating diseases,” said Benito Fernandez, Chief Commercial Officer. “We’re proud to be in the specialty pharmacy network for Leqembi. We’re confident this new medication will help more patients with Alzheimer’s get the right treatment to improve their quality of life.”
To learn more about CareMed and BrightSpring, please visit https://www.brightspringhealth.com/.
About BrightSpring Health Services
BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.
About CareMed Specialty Pharmacy
CareMed is an independent Specialty Pharmacy and clinical support services company within the BrightSpring enterprise. CareMed was founded to bring together the stakeholders involved in the chronic and rare disease treatment process and serve the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers. CareMed is headquartered in New Hyde Park, New York, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. It is accredited through URAC, ACHC, and NAPB as a Digital Pharmacy. For more information about CareMed, please visit www.CareMedSP.com.
Media Contact
Leigh White
This email address is being protected from spambots. You need JavaScript enabled to view it.
502.630.7412
Last Trade: | US$23.93 |
Daily Change: | 0.12 0.50 |
Daily Volume: | 2,134,529 |
Market Cap: | US$4.170B |
May 02, 2025 March 06, 2025 November 26, 2024 November 01, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load